Not in the current Orange Book — This application is not listed in FDA's current Orange Book data files (no listed patents or exclusivities). Product and approval data shown are from FDA's Drugs@FDA database.
LAMIVUDINE; ZIDOVUDINE
NDANot in Orange Book
LAMIVUDINE; ZIDOVUDINE | N204914 | MYLAN LABS
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 30MG; 60MG
▴
TABLET; ORAL SUSPENSION | Approved: Feb. 4, 2014
No patent or exclusivity listings for this strength.